“…Here, we focus on a specific topic: our current knowledge concerning the definition and recognition of SARS-CoV-2-derived T cell epitopes in humans. While the data related to this topic was initially sparse, 25 different studies have now been published as of March 15, 2021 (Chen et al, 2021;Ferretti et al, 2020;Gangaev et al, 2020;Habel et al, 2020;Joag et al, 2021;Kared et al, 2021;Keller et al, 2020;Le Bert et al, 2021Lee et al, 2020;Mahajan et al, 2020;Mateus et al, 2020;Nelde et al, 2021;Nielsen et al, 2020;Peng et al, 2020;Poran et al, 2020bPoran et al, , 2020aPrakash et al, 2020;Rha et al, 2021;Sahin et al, 2020;Saini et al, 2020, 2021, Schulien et al, 2021Sekine et al, 2020;Shomuradova et al, 2020;Snyder et al, 2020;Tarke et al, 2021a), which collectively report data from 1,197 human subjects (870 COVID-19 and 327 unexposed controls), leading to the identification of over 1,400 different CD4 (n = 382) and CD8 (n = 1052) T cell epitopes. These studies are listed in Table 1, which also captures whether these studies defined class I/CD8 epitopes and/or class II/CD4 epitopes.…”